Highlights in Multiple Myeloma From ASH 2022

Joseph Mikhael, MD


January 03, 2023

Dr Joseph Mikhael, from City of Hope Cancer Center in Phoenix, Arizona, discusses highlights of the latest research in multiple myeloma presented at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition.

Dr Mikhael starts with a trial of the T-cell–directed bispecific antibody talquetamab in patients with relapsed/refractory disease. The novel treatment showed promise, achieving a high response rate with relatively few and typically mild infections.

Also in the relapsed/refractory setting, he discusses a trial of elranatamab, a BCMA-targeted bispecific antibody, for which response rates were high and progression-free survival was notable.

Dr Mikhael next turns to a study that examined racial and ethnic differences in clinical outcomes among patients treated with CAR-T cell therapy. The sobering results suggest that more work is needed to reduce differences in outcomes.

His fourth choice is a trial of the immune-targeting attenuated cytokine modakafusp alfa, which showed encouraging activity in patients with relapsed/refractory disease.

In closing, Dr Mikhael looks at a dose-expansion study of the novel oral agent mezigdomide plus dexamethasone. The combination was found to be efficacious, even in patients who had received at least three prior lines of therapy.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.